$HQY

Fiore Michael Henry sold $298K of HQY

Fiore Michael Henry (EVP, CHIEF COMMERCIAL OFFICER) sold 3,142 shares of HEALTHEQUITY, INC. (HQY) at $95.00 ($0.30M total) on 2026-05-29 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Fiore Michael Henry
Published Jun 2, 2026, 9:03 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 2, 2026, 9:07 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$HQY
Neutral
medium confidence
Mentioned
$HQY
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$HQYNeutralLow
01

Why it matters

The disclosed sale is under a pre-arranged 10b5-1 plan, typically viewed as lower information content than unscheduled selling.

02

Market read

Traders may monitor for follow-on insider activity, but this specific disclosure alone is unlikely to drive a fundamental repricing.

03

What to watch

The filing excerpt doesn’t state total compensation context, diversification needs, or whether other insiders are buying/selling around the same period.

Relevance 6/10Novelty 6/10Timing: SEC Form 4 filed today; sale occurred on 2026-05-29

Background

The article is a SEC EDGAR Form 4 insider transaction disclosure for HEALTHEQUITY (HQY).

Company-level read

Ticker impact

$HQYNeutralMedium confidence
Context

HEALTHEQUITY’s EVP/Chief Commercial Officer sold 3,142 shares in an open-market transaction disclosed on SEC Form 4.

Expected impact

Likely limited near-term impact; any effect is more about positioning/flow than new fundamentals.

Evidence & confidence

Form 4 shows a scheduled 10b5-1 sale (not discretionary timing), with no accompanying earnings, guidance, or operational change in the filing excerpt.

Market effects

Minimal—this is company-specific insider activity with no sector-wide catalyst indicated.

None indicated.

None indicated.

Counterpoint

Even with a 10b5-1 plan, repeated insider selling can still coincide with internal risk perceptions; traders may treat it as a mild caution signal.

Key entities

  • HEALTHEQUITY, INC.

    Subject of the Form 4 insider transaction; shares sold by an EVP/Chief Commercial Officer.

  • Fiore Michael Henry

    EVP, Chief Commercial Officer who sold 3,142 shares at $95.00 on 2026-05-29 (reported via Form 4 filed 2026-06-02).

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$HQYHighAI 8/10

HealthEquity (HQY) Q2 2027 Earnings Call Transcript

HealthEquity (HQY) reported Q2 2027 revenue of $350.7M, up 8% YoY, and adjusted EBITDA of $167M, up 11%. HSA assets grew 14% to $37.9B. The company raised full-year revenue guidance to $1.411B-$1.421B and adjusted EBITDA to $628M-$636M. Management highlighted growth in custodial and service revenue, as well as operational efficiencies from AI and technology investments.

$HQYMed

Why HealthEquity Stock Sank This Week

HealthEquity (HQY) stock fell 8.6% this week despite beating earnings and revenue estimates for Q2. The company reported adjusted EPS of $1.24 on revenue of $350.7M, up 15.7% and 7.6% YoY, respectively. Investors expected stronger guidance, as the company only slightly raised its full-year revenue target and reiterated EPS guidance.